Phase 3 N=47 Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD
Diabetes, Type I · Diabetes, Type II · Angina
Primary: Change in Post-exercise Coronary Vasodilator Reserve — -4; 2 % change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=30 Feasibility and Efficacy of Coronary Sinus Narrowing in Patients With Coronary Microvascular Dysfunction
Coronary Microvascular Dysfunction
Primary: Change in Coronary Flow Reserve (CFR) — 3.04 ratio — p=0.0137
Phase 2 N=34 Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
Metabolic Syndrome · Coronary Microvascular Dysfunction
Primary: Absolute Change in Coronary Cross-sectional Area (in mm²) Within the Vericiguat Group as Assessed by Magnetic Resonance Imaging (MRI) — -1.11; 0.40 mm^2 — p=0.0005
N/A N=80 Genetic Determinants of the Coronary Microvascular Obstruction in PCI
Myocardial Infarction · No-Reflow Phenomenon
Primary: Hospital Mortality Rate — 6; 2 Participants
N/A N=7 Impact of Ranolazine on Coronary Microcirculatory Resistance
Coronary Microcirculation · Coronary Artery Disease · Myocardial Disease
Primary: Number of Participants Assessed for Relative Change in the Index of Microcirculatory Resistance Before and After Ranolazine Therapy — 7 Participants
N/A N=142 Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia
Microvascular Coronary Dysfunction (MCD)
Primary: Seattle Angina Questionnaire (SAQ) — 68.09; 66.7; 58.4; 51.17 Units on scale
Phase 2 N=20 Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease
Coronary Microvascular Dysfunction
Primary: Change From Baseline in Coronary Flow Reserve — 0.62 ratio
Phase 2 N=23 Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI
Myocardial Reperfusion Injury
Primary: Average Peak Velocity (APV) Immediately Following Percutaneous Coronary Intervention (PCI) — 30; 19 cm/s — p=0.029
Phase 4 N=12 Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease
Microvascular Angina
Primary: Seattle Angina Questionnaire Score — 83.3; 29.2; 74.1; 67.6 units on a scale
Phase 2 N=20 Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI
Myocardial Ischemia
Primary: Quantification of Myocardial Blood Volume — 3.63; 1.23 seconds^-1
Phase 2 N=20 Microvascular Coronary Disease In Women: Impact Of Ranolazine
Myocardial Ischemia
Primary: Cardiac Magnetic Resonance (CMRs) — 11.7; 16.0 Percentage of ischemic myocardium
N/A N=116 COronary and MICrocirculatory Measurements in Patients With Aortic Valve Stenosis.
Aortic Stenosis · Coronary Artery Disease
Primary: FFR 6 Months After SAVR/TAVI. — -0.0279 ratio
Phase 4 N=36 MIcrovascular dysfuNction In Moderate-severe Psoriasis
Psoriasis · Cardiovascular Disease
Primary: Change in Global Coronary Flow Reserve (CFR) After 6 Months of Therapy With Tildrakizumab — -0.03 CFR Ratio
Phase 2 N=26 Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)
Microvascular Angina
Primary: Change in Seattle Angina Questionnaire Score Regarding Angina Frequency — 0.70; 0.27 score on a scale
Phase 4 N=31 Ranolazine and Microvascular Angina by PET in the Emergency Department
Microvascular Angina
Primary: Coronary Flow Reserve — 1.6; 1.6; 1.9; 1.6 ratio
Phase 2 N=94 Inflammation and Coronary Endothelial Function
Coronary Artery Disease
Primary: Percent Change in Coronary Cross Sectional Area (CSA) From Rest to That During Isometric Handgrip Exercise (IHE) — -1.70; 2.71; -0.39; 2.04 Percent change from rest…
N/A N=50 Coronary Flow Reserve to Assess Cardiovascular Inflammation (CIRT-CFR)
Coronary Heart Disease · Metabolic Syndrome · Diabetes Mellitus
Primary: Change in Global Myocardial Blood Flow in Response to Vasodilator — 0.05; -0.145 percentage change in CFR
Phase 4 N=51 EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia
Ischemic Heart Disease
Primary: Epicardial Coronary Artery Endothelial Function (Adjusted) at Week 16 Comparing the Eplerenone Group to the Placebo Group — -1.2; -10.7 % change wk16-%change wk0…
Phase 4 N=14 Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction
Heart Transplant · Acute Graft Rejection · Chronic Graft Rejection
Primary: Myocardial Perfusion Reserve — 1.52; 1.94 arbitrary units
N/A N=2,349 Stress CMR Perfusion Imaging in the United States (SPINS) Study
Myocardial Ischemia
Primary: Cardiovascular Mortality — 74 Participants
N/A N=256 The Clinical Diagnosis Meaning of MIF in Coronary Heart Disease
Coronary Heart Disease
Primary: Comparison Between Coronary-artery-disease Group and Non-coronary-artery-disease Group on MIF Concentration — 48.08; 66.79 MIF Concentration,ug/L
Phase 4 N=54 Effects of Nicorandil on Angina Symptoms in Patients With Coronary Slow Flow
Slow Coronary Flow · Normal, or Near Normal Coronary Angiography · Stable Angina
Primary: Angina Episode Frequnecy — 2.28; 1.68 episodes per week
N/A N=120 Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging
Coronary Disease
Primary: Ability to Detect Stress-induced Myocardial Perfusion Abnormalities by Analysis of MDCT Images Confirmed by Coronary Angiography and/or SPECT. — 78 % accurately detected…
N/A N=21 PET MYOCARDIAL Blood Flow Comparison to Coronary CTA and CT-FFR
Coronary Artery Disease
Primary: Number of Flow-limiting Coronary Artery Stenosis on CT — 8 Coronary arteries
N/A N=242 Assessing Microvascular Resistance Via IMR To Predict Cumulative Outcome in STEMI Patients Undergoing Primary PCI
Multi Vessel Coronary Artery Disease · STEMI
Primary: Composite of: Cardiovascular Death*, Re-myocardial Infarct, Re-hospitalization for Heart Failure (HF) and Congestive Heart Failure (CHF), Resuscitation or ICD…
N/A N=105 Randomized Investigation of Chest Pain Diagnostic Strategies
Acute Coronary Syndrome · Chest Pain
Primary: The Composite of Revascularization, Re-hospitalization, and Recurrent Cardiac Testing Through 90 Days. — 7; 20 participants
Phase 3 N=478 Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
Coronary Artery Disease
Primary: Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Primary Analysis of Sensitivity Based on Blinded…
Phase 3 N=40 Comprehensive Evaluation of Ischemic Heart Disease Using MRI
Heart Disease, Ischemic · Atherosclerosis, Coronary
Primary: Magnetic Resonance Image Quality Rating — 3.57; 2.55 units on a likert scale — p=<0.001
N/A N=150 Stress CT Perfusion in Patients With Chest Pain
Coronary Artery Disease
Primary: Number of Participants With Detected Stress-induced Perfusion Abnormalities by 3D Analysis of MDCT Images — 56 Participants
Phase 2 N=81 Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV
Coronary Artery Disease · Human Immunodeficiency Virus
Primary: Coronary Endothelial Function Measured by Percent Change in Coronary Blood Flow With Exercise (%) at 8 Weeks — 8.1; 13.4 Percent change from rest measurement